Telemedical, Intersectoral Network as New Digital Health Structure to Measurably Improve the Local Health Care (TELnet@NRW)
연구 개요
상세 설명
In future time the number of old people will significantly increase in Germany because of the demographic change taking place. The health care of the large number of old people will probably lead to a lack of physicians and an inefficient health care system. One strategy to tackle the problem could be telemedicine. Telemedicine makes it possible to provide know-ledge from experts to local hospitals and practices which otherwise need to send patients with serious and complex diseases to specialized trans-regional health centers. In this multicenter, prospective, non-interventional study hospitals and practices in NRW are supplied via a telematics platform with expert know-ledge from the university hospitals RWTH Aachen and Münster. The communication occurs via highly encrypted audio/video conference systems and a certified data exchange platform "Fallakte+".
In total 40.000 outpatient and stationary patients should be treated with telemedical support. Registered doctors will be involved in already existing practice networks to evaluate the potential for transfer and to ensure the sharing of know-ledge beyond the borders of individual sectors. The aim of the study is to improve the treatment quality of regional hospitals and practices and to increase the efficiency of the care of relevant patient cohort in the field of infectiology and intensive care with the main focus sepsis as those patient groups especially often require professional expertise for a successful therapy.
In the beginning of the study participating hospitals and practices are randomly distributed into four clusters (cluster randomization). The different clusters all start with the control phase but enter into the intervention phase at different times (stepped-wedge design). During the control phase data of patients with infection and intensive care patients routinely treated without the support of telemedicine are documented and the patients are asked to complete a questionnaire regarding health-related quality of life (SF36) directly after treatment and at two time points in the follow-up. The collected data will be later compared to data obtained in the same way from patients treated with telemedical support and evaluated regarding differences in the quality of treatment, therapeutic process and the satisfaction of the patients with telemedicine.
If the study shows that the treatment quality and therapeutic process of patients with infectious diseases or need for intensive care is improved by telemedicine, the telematics platform can be expanded and used by other specialized fields and users in future time.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Münster, 독일
- University Hospital Münster
-
-
NRW
-
Aachen, NRW, 독일, 52074
- University Hospital RWTH Aachen
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- majority
- written informed consent
- infectiological and/or intensive care treatment
Exclusion Criteria:
- minority
- absence of written informed consent in the case of non-acute life-threatening disease
- persons who have a dependency or employment relationship with the sponsor or investigator
- persons who are sheltered in an institution upon court or administrative order
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Control
Patients of this group are routinely treated without telemedical support.
|
|
|
활성 비교기: Telemedical support
Patients of this group are routinely treated with telemedical support.
|
Participating sites will be advised by telemedicine support.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Improvement of treatment quality
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
The level of implementation of the 10 recommendations of the German Society of Infectious Diseases (Deutsche Gesellschaft für Infektiologie, DGI) within the framework of the Initiative "Decide wisely" ("Klug entscheiden").
|
through study completion, an average of 30 days up to a maximum of 1 year
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate of sepsis diagnosis
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
Rate of sepsis diagnosis
|
through study completion, an average of 30 days up to a maximum of 1 year
|
|
Rate of ARDS Diagnosis
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
Rate of ARDS Diagnosis
|
through study completion, an average of 30 days up to a maximum of 1 year
|
|
Sepsis therapy in compliance with guidelines
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
Sepsis therapy in compliance with guidelines through for instance timely administration of antibiotics within 3 h and reduction of sepsis mortality.
|
through study completion, an average of 30 days up to a maximum of 1 year
|
|
Rate of ARDS therapy according to guidelines
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
Measured against the evident ventilation targets, Ventilation with low ventilation volumes and low peak pressures: with controlled ventilation: Breath volume of 6 ml/kg calculated Body ideal weight, PEEP setting in proportion with the necessary FiO2, plateau pressure < 30 cm H2O |
through study completion, an average of 30 days up to a maximum of 1 year
|
|
Rate of inadequate antibiotic therapies
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
Measured by the Percentage of postoperatively continued perioperative Antibiotic prophylaxis
|
through study completion, an average of 30 days up to a maximum of 1 year
|
|
Rate of patients with dialysis
기간: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Rate of patients with dialysis requiring Kidney insufficiency in discharge from the Intensive care
|
At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
|
Rate of transfer transport
기간: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Rate of transfer transport
|
At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
|
Health-related quality of life (SF36-Questionnaire)
기간: At discharge from Intensive Care Unit (through study completion; an average of 30 days up to a maximum of 1 year), through study completion, an average of 12 months and 24 months after discharge of ICU
|
Clinical studies 36-item Medical Outcomes Study Short-Form General Health Survey An instrument used to assess multidimensional health-related QOL, which measures 8 health related parameters: physical function, social function, physical role, emotional role, mental health, energy, pain, general health perceptions; each parameter is scored from 0 to 100 Managed care 36-Item Short-Form Functional and Perceived Health Status Survey A questionnaire which measures health status; the SF-36 also includes a list of 18 self-reported chronic conditions
|
At discharge from Intensive Care Unit (through study completion; an average of 30 days up to a maximum of 1 year), through study completion, an average of 12 months and 24 months after discharge of ICU
|
|
Rate of non-diagnosed sepsis
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
Defined as no filled out sepsis bundle despite presence of sepsis symptoms
|
through study completion, an average of 30 days up to a maximum of 1 year
|
|
Sepsis mortality rate
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
Sepsis mortality rate
|
through study completion, an average of 30 days up to a maximum of 1 year
|
|
Hospital mortality rate
기간: through study completion, an average of 30 days up to a maximum of 1 year
|
Hospital mortality rate
|
through study completion, an average of 30 days up to a maximum of 1 year
|
|
Length of stay in intensive care unit
기간: At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
Length of stay in intensive care unit measured in hours
|
At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
|
|
Hospital stay
기간: At discharge from Hospital; after an average of 30 days up to a maximum of 1 year
|
Hospital stay measured in days
|
At discharge from Hospital; after an average of 30 days up to a maximum of 1 year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Gernot Marx, Univ.-Prof. Dr. med., Clinic for Operative Intensive Care and Intermediate Care, University Hospital RWTH Aachen
간행물 및 유용한 링크
일반 간행물
- Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007 Apr;33(4):606-18. doi: 10.1007/s00134-006-0517-7. Epub 2007 Feb 24.
- Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Grundling M, John S, Kern W, Kreymann G, Kruger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stuber F, Weiler N, Weimann A, Werdan K, Welte T; German Sepsis Society; German Interdisciplinary Association of Intensive Care and Emergency Medicine. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinare Vereinigung fur Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci. 2010 Jun 28;8:Doc14. doi: 10.3205/000103.
- Laxminarayan R, Bhutta Z, Duse A, Jenkins P, O'Brien T, Okeke IN, Pablo-Mendez A, Klugman KP. Drug Resistance. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006. Chapter 55. Available from http://www.ncbi.nlm.nih.gov/books/NBK11774/
- Marx G, Greiner W, Juhra C, Elkenkamp S, Gensorowsky D, Lemmen S, Englbrecht J, Dohmen S, Gottschalk A, Haverkamp M, Hempen A, Flugel-Bleienheuft C, Bause D, Schulze-Steinen H, Rademacher S, Kistermann J, Hoch S, Beckmann HJ, Lanckohr C, Lowitsch V, Peine A, Juzek-Kuepper F, Benstoem C, Sperling K, Deisz R. An Innovative Telemedical Network to Improve Infectious Disease Management in Critically Ill Patients and Outpatients (TELnet@NRW): Stepped-Wedge Cluster Randomized Controlled Trial. J Med Internet Res. 2022 Mar 2;24(3):e34098. doi: 10.2196/34098.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- 16-162
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Telemedical support에 대한 임상 시험
-
Medical University of South CarolinaNational Institutes of Health (NIH)모병
-
Medical University of South CarolinaNational Center for Advancing Translational Sciences (NCATS)완전한
-
University of CalgaryAlberta Health services; University of Alberta; Covenant Health완전한
-
Seoul National University HospitalAjou University School of Medicine; Soonchunhyang University Hospital; Saint Vincent's Hospital... 그리고 다른 협력자들완전한
-
The University of Hong Kong모집하지 않고 적극적으로
-
UConn HealthUniversity of Texas at Austin; Oregon Social Learning Center모집하지 않고 적극적으로
-
Women's College HospitalToronto Metropolitan University빼는
-
University of OregonSpecial X Inc.완전한부모-자녀 관계 | 육아 | 아동 행동 | 발달 장애 | 개발 지연 | 발달 장애, 아동미국
-
Oregon Health and Science University모집하지 않고 적극적으로상처와 부상 | 통증 관리 | 인간 공학미국
-
Dana-Farber Cancer Institute빼는